Group 1 - The core point of the news is that Shouyao Holdings experienced a decline of 5.09% in its stock price, reaching 39.13 yuan per share, with a total market capitalization of 5.819 billion yuan as of the report date [1] - Shouyao Holdings, established on April 19, 2016, and listed on March 23, 2022, is primarily engaged in the research and development of small molecule anti-tumor drugs, with 100% of its revenue coming from technology development and services [1] Group 2 - From the perspective of fund holdings, Guotai Fund has a significant position in Shouyao Holdings through its fund Guotai Innovation Medical Mixed Initiation A (018159), which held 26,200 shares, accounting for 4.77% of the fund's net value, making it the eighth largest holding [2] - The fund Guotai Innovation Medical Mixed Initiation A was established on April 18, 2023, with a latest scale of 17.7778 million yuan, and has achieved a year-to-date return of 49.23%, ranking 1171 out of 8148 in its category [2] - The fund manager, Qiu Xiaoxu, has a tenure of 3 years and 85 days, with the fund's total asset size at 676 million yuan, achieving a best return of 14.1% and a worst return of 1.44% during his management period [2]

Group 1 - The core viewpoint of the news is that Shouyao Holdings experienced a decline in stock price and trading volume, indicating potential liquidity issues and investor sentiment concerns [1] - On October 13, Shouyao Holdings' stock price fell by 2.86%, with a trading volume of 43.49 million yuan, and a net financing buy of -48,200 yuan [1] - As of October 13, the total margin balance for Shouyao Holdings was 287 million yuan, accounting for 11.04% of its market capitalization, which is above the 80th percentile of the past year [1] Group 2 - As of June 30, the number of shareholders for Shouyao Holdings increased by 5.33% to 4,526, while the average circulating shares per person decreased by 5.06% to 14,141 shares [2] - For the first half of 2025, Shouyao Holdings reported a revenue of 2 million yuan, a year-on-year decrease of 47.37%, and a net profit attributable to shareholders of -104 million yuan, a decrease of 1.48% year-on-year [2] - Among institutional holdings, as of June 30, 2025, Penghua Medical Technology Stock A was the largest shareholder with 5.41 million shares, unchanged from the previous period, while China Europe Medical Health Mixed A entered as the tenth largest shareholder with 1.17 million shares [2]

Group 1 - The core point of the news is that Shouyao Holdings experienced a decline of 5.01% in its stock price, reaching 42.81 CNY per share, with a total market capitalization of 6.367 billion CNY [1] - Shouyao Holdings, established on April 19, 2016, and listed on March 23, 2022, specializes in the research and development of small molecule anti-tumor drugs, with 100% of its revenue coming from technology development and services [1] Group 2 - From the perspective of fund holdings, Shouyao Holdings is a top ten holding for the Tongtai Health Theme Mixed A Fund (011002), which held 28,100 shares, accounting for 4.52% of the fund's net value [2] - The Tongtai Health Theme Mixed A Fund has a current scale of 6.1823 million CNY and has achieved a year-to-date return of 29.88%, ranking 3611 out of 8166 in its category [2] - The fund has experienced a floating loss of approximately 63,600 CNY today [2] Group 3 - The fund managers of Tongtai Health Theme Mixed A Fund are Ma Yi and Mai Jianpei, with Ma Yi having a tenure of 11 years and 208 days, managing assets totaling 6.063 billion CNY, and achieving a best fund return of 43.57% during his tenure [3] - Mai Jianpei has a tenure of 152 days, managing assets of 161 million CNY, with a best fund return of 32.24% during his short tenure [3]

Group 1 - On September 25, Shouyao Holdings experienced a decline of 1.22% with a transaction volume of 98.81 million yuan [1] - The financing data indicates that on the same day, Shouyao Holdings had a financing purchase amount of 6.27 million yuan and a financing repayment of 14.44 million yuan, resulting in a net financing outflow of 8.17 million yuan [1] - As of September 25, the total balance of margin trading for Shouyao Holdings was 292 million yuan, accounting for 9.57% of its circulating market value, which is above the 90th percentile level over the past year [1] Group 2 - As of June 30, the number of shareholders of Shouyao Holdings increased by 5.33% to 4,526, while the average circulating shares per person decreased by 5.06% to 14,141 shares [2] - For the first half of 2025, Shouyao Holdings reported an operating income of 2 million yuan, a year-on-year decrease of 47.37%, and a net profit attributable to shareholders of -104 million yuan, a decrease of 1.48% year-on-year [2] - Among institutional holdings, as of June 30, 2025, Penghua Medical Technology Stock A was the largest circulating shareholder with 5.41 million shares, unchanged from the previous period, while China Europe Medical Health Mixed A entered as the tenth largest shareholder with 1.17 million shares [2]

Group 1 - The core viewpoint of the news is that Shouyao Holdings has seen a significant increase in its stock price, rising by 5.01% to reach 46.57 yuan per share, with a total market capitalization of 6.926 billion yuan [1] - Shouyao Holdings, established on April 19, 2016, specializes in the research and development of small molecule anti-tumor drugs, with its main business revenue entirely derived from technology development and services [1] - The trading volume for Shouyao Holdings was 62.3524 million yuan, with a turnover rate of 2.14% [1] Group 2 - According to data, a fund under Jianxin Fund has Shouyao Holdings as one of its top ten holdings, specifically Jianxin High-end Medical Stock A (004683), which held 121,900 shares, accounting for 3.53% of the fund's net value [2] - The fund has realized a floating profit of approximately 270,700 yuan from its investment in Shouyao Holdings [2] - Jianxin High-end Medical Stock A has achieved a year-to-date return of 16.98% and a one-year return of 23.22%, ranking 2964 out of 4222 and 3576 out of 3802 in its category, respectively [2] Group 3 - The fund manager of Jianxin High-end Medical Stock A is Pan Longling, who has been in the position for 9 years and 172 days, with the fund's total asset size currently at 160 million yuan [3] - During Pan Longling's tenure, the best fund return was 60.05%, while the worst return was -30.58% [3]